<DOC>
	<DOCNO>NCT01471158</DOCNO>
	<brief_summary>The purpose study assess patient preference AZARGA® compare COSOPT® single drop medication administer eye , patient open-angled glaucoma ocular hypertension .</brief_summary>
	<brief_title>Patient Preference Comparison AZARGA Versus COSOPT Patients With Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension , primary openangle pigment dispersion glaucoma eye . On stable regimen intraocular pressure ( IOP ) lower medication within 30 day screen visit . IOP consider safe ( opinion investigator ) eye way assure clinical stability vision optic nerve throughout study period . Willing discontinue use ocular drug ( prescribe overthecounter ) prior receive screen dose Screening Visit course study . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity , poor tolerance component preparation use study deem clinical significant opinion Principal Investigator . Corneal dystrophies either eye . Risk visual field visual acuity worsen consequence participate study , investigator 's best judgment . Bronchial asthma history bronchial asthma , severe chronic obstructive pulmonary disease would preclude safe administration topical betablocker . History severe allergic rhinitis . Participation investigational study within 30 day prior Screening/Baseline Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Primary open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>pigment dispersion glaucoma</keyword>
</DOC>